Cargando…
Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
COVID-19, caused by SARS-CoV-2, is currently spreading around the world and causing many casualties. Antibodies against such emerging infectious diseases are one of the important tools for basic viral research and the development of diagnostic and therapeutic agents. CR3022 is a monoclonal antibody...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310559/ https://www.ncbi.nlm.nih.gov/pubmed/34304364 http://dx.doi.org/10.1007/s12033-021-00373-0 |
_version_ | 1783728785822056448 |
---|---|
author | Ebihara, Takeru Masuda, Akitsu Takahashi, Daisuke Hino, Masato Mon, Hiroaki Kakino, Kohei Fujii, Tsuguru Fujita, Ryosuke Ueda, Tadashi Lee, Jae Man Kusakabe, Takahiro |
author_facet | Ebihara, Takeru Masuda, Akitsu Takahashi, Daisuke Hino, Masato Mon, Hiroaki Kakino, Kohei Fujii, Tsuguru Fujita, Ryosuke Ueda, Tadashi Lee, Jae Man Kusakabe, Takahiro |
author_sort | Ebihara, Takeru |
collection | PubMed |
description | COVID-19, caused by SARS-CoV-2, is currently spreading around the world and causing many casualties. Antibodies against such emerging infectious diseases are one of the important tools for basic viral research and the development of diagnostic and therapeutic agents. CR3022 is a monoclonal antibody against the receptor binding domain (RBD) of the spike protein (S protein) of SARS-CoV found in SARS patients, but it was also shown to have strong affinity for that of SARS-CoV-2. In this study, we produced large amounts of three formats of CR3022 antibodies (scFv, Fab and IgG) with high purity using a silkworm-baculovirus expression vector system. Furthermore, SPR measurements showed that the affinity of those silkworm-produced IgG antibodies to S protein was almost the same as that produced in mammalian expression system. These results indicate that the silkworm-baculovirus expression system is an excellent expression system for emerging infectious diseases that require urgent demand for diagnostic agents and therapeutic agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12033-021-00373-0. |
format | Online Article Text |
id | pubmed-8310559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-83105592021-07-26 Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System Ebihara, Takeru Masuda, Akitsu Takahashi, Daisuke Hino, Masato Mon, Hiroaki Kakino, Kohei Fujii, Tsuguru Fujita, Ryosuke Ueda, Tadashi Lee, Jae Man Kusakabe, Takahiro Mol Biotechnol Original Paper COVID-19, caused by SARS-CoV-2, is currently spreading around the world and causing many casualties. Antibodies against such emerging infectious diseases are one of the important tools for basic viral research and the development of diagnostic and therapeutic agents. CR3022 is a monoclonal antibody against the receptor binding domain (RBD) of the spike protein (S protein) of SARS-CoV found in SARS patients, but it was also shown to have strong affinity for that of SARS-CoV-2. In this study, we produced large amounts of three formats of CR3022 antibodies (scFv, Fab and IgG) with high purity using a silkworm-baculovirus expression vector system. Furthermore, SPR measurements showed that the affinity of those silkworm-produced IgG antibodies to S protein was almost the same as that produced in mammalian expression system. These results indicate that the silkworm-baculovirus expression system is an excellent expression system for emerging infectious diseases that require urgent demand for diagnostic agents and therapeutic agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12033-021-00373-0. Springer US 2021-07-25 2021 /pmc/articles/PMC8310559/ /pubmed/34304364 http://dx.doi.org/10.1007/s12033-021-00373-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Original Paper Ebihara, Takeru Masuda, Akitsu Takahashi, Daisuke Hino, Masato Mon, Hiroaki Kakino, Kohei Fujii, Tsuguru Fujita, Ryosuke Ueda, Tadashi Lee, Jae Man Kusakabe, Takahiro Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System |
title | Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System |
title_full | Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System |
title_fullStr | Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System |
title_full_unstemmed | Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System |
title_short | Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System |
title_sort | production of scfv, fab, and igg of cr3022 antibodies against sars-cov-2 using silkworm-baculovirus expression system |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310559/ https://www.ncbi.nlm.nih.gov/pubmed/34304364 http://dx.doi.org/10.1007/s12033-021-00373-0 |
work_keys_str_mv | AT ebiharatakeru productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT masudaakitsu productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT takahashidaisuke productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT hinomasato productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT monhiroaki productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT kakinokohei productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT fujiitsuguru productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT fujitaryosuke productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT uedatadashi productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT leejaeman productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem AT kusakabetakahiro productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem |